- Home
- BPT vs CODX Comparison
BPT vs CODX Comparison
Compare BPT & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPT
- CODX
- Stock Information
- Founded
- BPT 1989
- CODX 2013
- Country
- BPT United States
- CODX United States
- Employees
- BPT N/A
- CODX N/A
- Industry
- BPT Integrated oil Companies
- CODX Medical/Dental Instruments
- Sector
- BPT Energy
- CODX Health Care
- Exchange
- BPT Nasdaq
- CODX Nasdaq
- Market Cap
- BPT 11.7M
- CODX 11.9M
- IPO Year
- BPT N/A
- CODX 2017
- Fundamental
- Price
- BPT $0.63
- CODX $0.30
- Analyst Decision
- BPT
- CODX Buy
- Analyst Count
- BPT 0
- CODX 2
- Target Price
- BPT N/A
- CODX $5.50
- AVG Volume (30 Days)
- BPT 76.0K
- CODX 719.9K
- Earning Date
- BPT 06-17-2025
- CODX 05-08-2025
- Dividend Yield
- BPT N/A
- CODX N/A
- EPS Growth
- BPT N/A
- CODX N/A
- EPS
- BPT N/A
- CODX N/A
- Revenue
- BPT $211,000.00
- CODX $3,497,583.00
- Revenue This Year
- BPT N/A
- CODX N/A
- Revenue Next Year
- BPT N/A
- CODX $42.11
- P/E Ratio
- BPT N/A
- CODX N/A
- Revenue Growth
- BPT N/A
- CODX N/A
- 52 Week Low
- BPT $0.40
- CODX $0.23
- 52 Week High
- BPT $2.61
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- BPT 52.72
- CODX 48.86
- Support Level
- BPT $0.61
- CODX $0.23
- Resistance Level
- BPT $0.67
- CODX $0.32
- Average True Range (ATR)
- BPT 0.03
- CODX 0.04
- MACD
- BPT -0.00
- CODX 0.01
- Stochastic Oscillator
- BPT 28.57
- CODX 67.38
About BPT BP Prudhoe Bay Royalty Trust
BP Prudhoe Bay Royalty Trust is a grantor trust operating in the US. The property of the Trust consists of an overriding royalty interest. The Royalty Interest entitles the Trust to receive the royalty from the production of crude oil and condensate from the working interest of BP Exploration (Alaska) Inc. in the Prudhoe Bay oil field located on the North Slope of Alaska.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.